Planview Continues Acceleration with Record Revenue in FY’22
30.1.2023 17:00:00 EET | Business Wire | Press release
Planview, the leading platform for connected work from portfolio planning to delivery, today announced record annual recurring revenue (ARR) for fiscal year 2022, continuing a trend of strong performance. Planview exceeded $380 million in total ARR for 2022, representing 17% growth year-over-year (YoY).
“It was another record year for Planview, underpinned by our commitment to build the digital future of connected work through product innovation and customer success,” said Razat Gaurav, Chief Executive Officer, Planview. “The macroeconomic uncertainties and headwinds faced by organizations today make prioritizing product and project initiatives, and thoughtfully allocating constrained resources and capital, more important than ever. Our global customer base relies on our solutions to help them achieve productivity, efficiency, and positive business outcomes from transformation initiatives across the enterprise.”
Fiscal Year-End Highlights
Planview achieved record levels for the full fiscal year 2022:
- Total revenue surpassed $410 million for the full year
- ARR grew by over 17% YoY to over $380M
- Record 25% increase in monthly active users YoY for leading products
- Customer retention rates are up 6% YoY
Strong New Logo and Customer Momentum Driven by Product Innovation
Key customer wins and expansions have driven Planview’s profitable growth. In 2022, the company added 482 net new customers. New and notable customers who selected or expanded their footprint with Planview include: Builders FirstSource, Inc., Delta Dental of California, DS Smith, Fonterra, General Motors, Maximus, Inc., Olam International Limited, Publicis, RxBenefits, Schluter, Siemens, Sysco Corporation, T-Mobile, The Emmes Company, LLC, Tetra Pak, and UiPath.
This growth was accelerated by the success of Planview’s connected platform of solutions, which helps organizations improve time-to-value, do more with the teams and resources allocated, and de-risk strategic investment decisions. Planview’s innovation over the past year continued to drive desired business outcomes for customers. Enhancements include:
- Expanding Objective and Key Results (OKRs) capabilities, enabling access to an embedded goal framework across the enterprise
- Introducing Time-to-Market dependency and outlier analytics, ensuring organizations can focus their investments and resources where they are most needed
- Extending visual planning and prioritization support and card automation capabilities, centrally defining planning and delivery increments and streamline productivity across multiple teams
- Enhancing UX/UI functionality
Additionally, the strategic acquisitions of Tasktop and Enrich in the first half of 2022 fueled Planview’s data science, planning, connectivity, and transformation offering. The Value Stream Management solution added last year, via the Tasktop acquisition, empowers organizations to accelerate their time to market, improve operational efficiency, and drive investment confidence in the face of economic disruption and instability.
Leading industry analyst firms have named Planview a leader in several key reports last year, reinforcing Planview’s leadership in Strategic Portfolio Management (SPM), Enterprise Agile Planning (EAP), Project and Portfolio Management (PPM), and Value Stream Management (VSM). Reports include:
- The Forrester Wave™: Strategic Portfolio Management Tools by Margo Visitacion, Chris Gardner, Stephen Lowers, Sarah Morana, Sara Sjoblom, Danielle Jessee, Kara and Hartig, Q1 2022
- Gartner, Magic Quadrant for Strategic Portfolio Management by Anthony Henderson and Daniel Stang, April 18, 2022
- Gartner, Magic Quadrant for Enterprise Agile Planning Tools by Bill Blosen, Mike West, Keith Mann, Deacon D.K. Wan, Akis Sklavounakis, Hassan Ennaciri, and Sarah Davies, April 25, 2022
- Gartner, Magic Quadrant for Adaptive Project Management and Reporting by Lorri Callahan, Sarah Davies, Daniel Stang, and Anthony Henderson, August 22, 2022
- The Forrester Wave™: Value Stream Management by Chris Condo, Q4 2022
Investing in Customer Success
To support continued customer success, training and learning were areas of strategic focus and investment. The company expanded a dedicated global learning team responsible for driving the Planview instructor-led training programs, developing new, engaging e-Learning offerings, and deploying a flagship learning management system, The University of Planview. The company also expanded its Evolve Advisory Services, supporting customers with the people and process change management that is required as part of business transformation.
To help deliver successful solutions to customers across the globe, faster, Planview also expanded its partner ecosystem, including new or expanded strategic relationships with the likes of Accenture, Atos, AWS, Deloitte, Infosys, and PwC, among others.
Planview Expands to Support Global Customer-base
Offering additional support for a more global customer base, Planview made strategic hires across its product development, customer success, sales, and marketing functions. Scaling up the company’s global operations, Planview opened a new regional office in Singapore and invested heavily in growing the company’s Global Capacity & Innovation Center in Bangalore, increasing its headcount in APAC by 65%.
To learn more about Planview, visit: www.planview.com.
About Planview
Planview has one mission: to build the future of connected work, from ideas to impact. Planview helps organizations accelerate the achievement of what matters most, supporting our customers from need to speed, from passion to progress, and from overhead to optimization. Our connected platform of solutions underpins the business and digital transformations of more than 4,500 customers globally, including 59 of the Fortune 100. Planview empowers enterprises to improve time-to-market and predictability, increase efficiency to unlock capacity, and ensure their most strategic initiatives deliver the desired business outcomes. Learn more about our portfolio at planview.com, and connect with us on LinkedIn and Twitter.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230130005394/en/
Contact information
Media Relations for Planview
Natalie Reina
Director of Corp Comms
956-878-9176
natalie.reina@planview.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 20:42:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 15:50:00 EEST | Press release
Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
